Sichenzia Ross Ference LLP Represents Inmune Bio, Inc. in a $40.0 Million Registered Direct Offering

Press Release – New York, New York – July 16, 2021 – Sichenzia Ross Ference LLP announced today that it represented Inmune Bio, Inc. (Nasdaq: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in a registered direct offering of common stock at a purchase price of $22.00 per share with two institutional investor. The gross proceeds from the offering were $40.0 million.
A.G.P./Alliance Global Partners acted as sole placement agent for the offering.
The Sichenzia Ross Ference LLP team was led by partners Marc Ross, Thomas Rose and Barrett DiPaolo.
- Sichenzia Ross Ference LLP Joins Cyngn Inc. in Ringing Opening Bell at Nasdaq MarketSite - May 12, 2022
- Gregory Sichenzia of Sichenzia Ross Ference LLP Quoted in Law360’s “IPO Lawyers See Mild Pickup in an Otherwise Cool Spring” - May 5, 2022
- Sichenzia Ross Ference LLP Represents Cyngn Inc. in $20 Million Private Placement Offering - May 2, 2022